Chembio Diagnostics (CEMI +18.8%) continues its torrid pace on almost double normal volume. Shares have rallied four-fold since touching $2.25 on March 16.
Investors have clearly liked the steady stream of developments since March 16 when the FDA announced that
it would allow the distribution of commercially developed COVID-19
tests prior to its OK for emergency use and the distribution of blood
tests if they are properly validated.
On March 20, the company announced a $4M order from Brazil for its DPP COVID-19 IgM/IgG point-of-care blood test.
On April 1, it announced the U.S. launch of the 15-minute test.
On April 9, Stony Brook Medical chose
the test for use in identifying people who have recovered from COVID-19
who could be donors for a study to assess the efficacy of convalescent
plasma in hospitalized patients.
https://seekingalpha.com/news/3560187-chembio-adds-to-covidminus-19-test-stoked-rally-up-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.